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Pharmacotherapy is the mainstay of hypertension manage-
ment though the selection of agents is essentially by trial-and-
error. Six drug classes are commonly used however response 
rates to any given drug, is around 50%.1 Antihypertensive 
drug development has stalled and there has been little prog-
ress in routine stratification by leveraging genomic and mo-
lecular information, despite potential benefit.2,3 Evidence is 
emerging of a novel pathway, mediated by the uromodulin 
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BACKGROUND
Genome-wide association studies have identified single nucleotide 
polymorphisms (SNPs) near the uromodulin gene (UMOD) affecting 
uromodulin excretion and blood pressure (BP). Uromodulin is almost 
exclusively expressed in the thick ascending limb (TAL) of the loop of 
Henle and its effect on BP appears to be mediated via the TAL sodium 
transporter, NKCC2. Loop-diuretics block NKCC2 but are not com-
monly used in hypertension management. Volume overload is one of 
the primary drivers for uncontrolled hypertension, so targeting loop-
diuretics to individuals who are more likely to respond to this drug 
class, using the UMOD genotype, could be an efficient precision med-
icine strategy.
METHODS
The BHF UMOD Trial is a genotype-blinded, multicenter trial 
comparing BP response to torasemide between individuals 
possessing the AA genotype of the SNP rs13333226 and those 
possessing the G allele. 240 participants (≥18 years) with uncon-
trolled BP, on ≥1 antihypertensive agent for ≥3 months, will receive 
treatment with Torasemide, 5 mg daily for 16 weeks. Uncontrolled 
BP is average home systolic BP (SBP) >135 mmHg and/or diastolic 
BP >85 mmHg. The primary outcome is the change in 24-hour am-
bulatory SBP area under the curve between baseline and end of 
treatment. Sample size was calculated to detect a 4 mmHg differ-
ence between groups at 90% power. Approval by West of Scotland 
Research Ethics Committee 5 (16/WS/0160). 
RESULTS
The study should conclude August 2021.
CONCLUSIONS
If our hypothesis is confirmed, a genotype-based treatment strategy for 
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(UMOD) gene (which is exclusively expressed in the kidney’s 
thick ascending limb (TAL) of the loop of Henle), that 
influences blood pressure (BP), with the potential to improve 
hypertension management and stimulate drug discovery.4 
In a large genome wide association study of BP extremes, 
the minor G allele of a UMOD promoter single-nucleotide 
polymorphism (SNP), rs13333226, was associated with a 
lower risk of hypertension (odds ratio [95% confidence in-
terval]: 0.87 [0.84; 0.91]) and reduced urinary uromodulin 
excretion.5 There are 3 SNPs in complete linkage disequi-
librium in the UMOD promoter region, rs12917707(G>T), 
rs4293393(A>G), and rs13333226(A>G) which show sim-
ilar associations in multiple genome wide association study 
studies. Each copy of the minor allele of these SNPs is as-
sociated with a lower risk of hypertension (odds ratio [95% 
confidence interval]: 0.87 [0.84–0.91], P  =  3.6  × 10−11),5 
0.49 mm Hg lower systolic BP (SBP) and 0.30 mm Hg lower 
diastolic BP (DBP) (P < 3 × 10−5),5,6 higher estimated glomer-
ular filtration rate (−0.0158 (SE = 0.0011), P = 9.47 × 10−43),7 
decreased risk of chronic kidney disease (1.24 [1.19–1.29], 
P = 1.98 × 10−25),7 and a lower level of urinary uromodulin 
excretion (−0.31 (0.018), P  =  3.4  × 10−64).8 Homozygous 
carriers of the risk allele (rs13333226(A), rs12917707(G), and 
rs4293393(A)) have twofold higher levels of uromodulin in 
the urine, compared with homozygous carriers of the minor 
(rs13333226(G), rs12917707(T), and rs4293393(G)) protec-
tive allele.9 Mechanistic studies in mouse models showed 
UMOD knockout mice had significantly lower SBP than 
wild-type mice, were resistant to salt-induced BP changes 
and demonstrated a left shift of the pressure–natriuresis 
curve.10 Trudu et  al. showed that UMOD overexpression 
caused a dose dependent increase in UMOD expression, as-
sociated with a BP increase.9 They also showed that loop-
diuretic treatment significantly enhanced natriuresis and 
reduced BP levels both in the transgenic mouse and in hyper-
tensive individuals homozygous for the UMOD increasing 
allele. These findings point to a novel pathway of BP and 
renal function regulation through interaction between the 
key Na+–K+–2Cl− cotransporter (NKCC2) in the TAL, which 
is specifically blocked by loop-diuretics, and uromodulin. 
These studies raise the possibility that hypertensive patients 
who possess the UMOD increasing allele will respond better 
to loop-diuretics. As volume overload is considered one of 
the primary drivers for uncontrolled hypertension, targeting 
loop-diuretics to individuals who are more likely to respond 
to this class would be a precision medicine strategy to im-
prove population hypertension control.
STUDY HYPOTHESIS
Our hypothesis is that based on the UMOD rs13333226 
genotype, there exists 2 strata of hypertensive patients who 
will show differential response to loop-diuretics based on their 
UMOD genotype. The high-UMOD group (homozygous for 
the major allele, AA genotype) with increased uromodulin 
excretion, greater salt sensitivity, hypertension, normal 
estimated glomerular filtration rate, and greater BP response 
to the loop-diuretic torasemide and the low-UMOD group (1 
or 2 copies of the G allele) with decreased uromodulin excre-
tion, greater salt resistance, increased estimated glomerular 
filtration rate, increased proximal tubular reabsorption of 
Na+ (possibly related to increased GFR), a poor BP response 
to loop-diuretics, and possibly diminished function of 
NKCC2. Our primary objective is to test whether hyperten-
sive subjects with uncontrolled BP possessing the rs13333226 
AA genotype will be better responders to loop-diuretics than 
those possessing the G allele.
METHODS
Study design
The British Heart Foundation (BHF) UMOD trial is a 
genotype-blinded, multicenter trial which will compare the 
BP response to torasemide between individuals possessing 
the AA genotype of the SNP rs13333226 and those possessing 
the G allele. Funding is by the BHF; CS/16/1/31878.
Study participants
Two hundred and forty participants aged ≥18 years from 
3 study sites (Dundee, Edinburgh, and Glasgow) will be 
prescribed torasemide for 16 weeks. Participants will have 
uncontrolled BP on ≥1 nondiuretic antihypertensive agent 
for ≥3 months prior to enrollment. Uncontrolled BP is de-
fined as average SBP >135  mm Hg and/or DBP >85  mm 
Hg on home BP monitoring (HBPM). Participants already 
taking a diuretic may be included if it safe to wash out this 
drug for a 2-week period prior to baseline visit. Study visits 
will be at week −2 (preexisting diuretics), 0, 2, 8, and 16. The 
study flow chart is shown in Figure 1 and the detailed partic-
ipant schedule is shown in Table 1. Full inclusion and exclu-
sion criteria are shown in Table 2.
Recruitment
Potential participants will be identified from secondary 
care BP clinics and general practice sites.
Participant consent and withdrawal
Interested participants will visit the study website (www.
bhfumod.co.uk) to complete initial consent, confirming they 
have read the participant information sheet and checking 
eligibility criteria. A  final check box marked “I have read, 
answered and understood all of the above questions and un-
derstand this is an electronic signature” must be ticked be-
fore proceeding to enrollment. A copy of the consent form 
and participant information sheet will be sent to the partic-
ipant electronically and a copy retained by the researchers. 
A  paper version of the participant information sheet and 
consent form will be available. Further written informed 
consent will be given at the initial study visit.
Screening
Consented, eligible participants will perform HBPM as 
detailed below. If HBPM criteria are met, a salivary DNA 
kit is used to collect the DNA sample which is returned 
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The genotype is entered in the electronic case report form 
(eCRF) by the laboratory technician who does not have ac-
cess to any of the trial data. The genotype is not disclosed to 
any of the trial personnel or the participant.
Study drug
Torasemide was chosen for this study as it is licensed for 
use in hypertension11 and has a longer half-life than the 
more commonly prescribed furosemide (4 vs. 1.5 hours), 
mitigating the secondary Renin Angiotensin System activa-
tion, and has a longer duration of action than furosemide 
(12 vs. 6 hours). This has enabled us to conduct this inno-
vative trial with torasemide without additional regulatory 
oversight and costs.
Torasemide will be initiated at 5 mg once daily, reducing 
to 2.5  mg once daily if required. The study drug will be 
supplied at weeks 0 and 8.
As with other diuretics, there may be disturbances of water 
and electrolyte balance. Hypokalemia and/or hyponatremia 
Figure 1. BHF UMOD study flow chart. Abbreviations: HBP, home blood pressure; ECG, electrocardiogram; HBPM, home blood pressure monitoring.
Table 1. Detailed participant schedule
Activity Screening
Treatment phase
Week −2a Week 0 Week 2 Week 4 Week 8 Week 12 Week 16
Clinic visit  X X X  X  X
Review eligibility X X X      
Informed consent X X X      
Salivary DNA sample X        
Demography X X X      
Medical history  X X     X
Medical examination  Xc Xc     Xc
Weight, height, BMI  X X   X  X
Medication review  X X X  X  X
Clinic blood pressure  X X X  X  X
Blood sampling  X X X  X  X
ECG   Xc     Xc
Urine sampling   Xb   X  Xb
ABPM   X   X  X
HBPM X    X  X  
Compliance check    X  X  X
Adverse events reporting    X  X  X
Dispense study medication   X   X   
Abbreviations: ABPM, ambulatory blood pressure monitoring; BMI, body mass index; ECG, electrocardiogram; HBPM, home blood pressure 
monitoring.
aIf on diuretics prior to study.
bIncluding pregnancy testing for women of childbearing potential.
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may occur. Other undesirable effects include elevated 
uric acid level, glucose, lipids, and decreases in platelets, 
white or red blood cells. There are known interactions 
with aminoglycosides, cephalosporins, lithium, theophyl-
line, non-steroidal anti-inflammatory drugs, digoxin, and 
sulphonylureas.
Table 2. Eligibility criteria
Inclusion criteria
 Hypertensive patients aged ≥18 years of age
  Patients will all have hypertension that is not controlled to home target: SBP >135 mm Hg and/or DBP >85 mm Hg on therapy with 
1 or more antihypertensive drugs for at least 3 months
 Able to attend one of the 3 study centers
Exclusion criteria
 Inability to give informed consent
 Participation in a clinical study involving an investigational drug or device within 3 months of screening
 Secondary or accelerated hypertension
 Diabetes mellitus (type 1 or type 2)
 eGFR <60 ml/minute, hyponatremia, hypokalemia
 Pregnancy, breast feeding
 Women of childbearing potential who are unwilling to use effective contraception
   Childbearing potential is defined as women who have experienced menarche and who have not undergone successful surgical 
sterilization or who are not postmenopausal (irregular menstrual periods, or amenorrhea >12 months, with serum follicle-
stimulating hormone (FSH) >35 mIU/ml; women taking hormone replacement therapy (HRT)
  Women of childbearing potential will be eligible if they are willing to use acceptable contraception (combined oral contraceptives, 
progesterone only contraceptives, intrauterine device, barrier methods) or they are abstinence due to lifestyle choice or their 
partner is sterile (vasectomy)
 Anticipated change of medical status during the trial (e.g., surgical intervention requiring >2 weeks convalescence)
 Recent (<6 months) cardiovascular event requiring hospitalization (e.g., myocardial infarction or stroke)
 Requirement for study drug or other loop-diuretic for reason other than to treat hypertension
  Clinically relevant contraindication to treatment with torasemide: hypersensitivity, hereditary problems of glucose intolerance, Lapp 
lactase deficiency of glucose–galactose malabsorption
 Current therapy for cancer
 Concurrent chronic illness, or other reasons likely to preclude 18-week participation in the study
  Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug 
or severely limit that patients life-span or ability to complete the study (e.g., alcohol or drug abuse, disabling or terminal illness, 
severe liver impairment, mental disorders)
 Treatment with any of the following medications
   Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study 
participation
   Chronic stable use, or unstable use of NSAIDs (other than low dose aspirin or occasional over the counter analgesic doses) 
is prohibited. Chronic use is defined as >3 consecutive days of treatment per week. In addition, intermittent use of NSAIDs 
is discouraged throughout the study. For those requiring analgesics during the study, paracetamol or opiate drugs are 
recommended
  Use of lithium
 Participants on the following medications may be included provided they meet the following criteria
   Use of thiazide or loop-diuretics prior to the study if the diuretic can be stopped for 2 weeks (washout) before the study 
medication administered
   The use of short acting nitrates (e.g., sublingual nitroglycerin) is permitted. However, participants should avoid short acting oral 
nitrates within 4 hours of screening or a subsequent visit
  The use of long acting nitrates (e.g., Isordil) is permitted but the dose must be stable for at least 2 weeks prior to screening
  The use of sympathomimetic decongestants is permitted, though not within 24 hours of any study visit/BP assessment
  The use of theophylline is permitted but the dose must be stable for at least 4 weeks prior to screening and throughout the study
   The use of phosphodiesterase type V inhibitors is permitted. However, study participants must refrain from taking these 
medications for at least 7 days prior to screening or any subsequent study visit
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NSAIDs, non-steroidal anti- 








undee user on 22 M
arch 2021
96 American Journal of Hypertension 34(1) January 2021
McCallum et al.
Drug adherence
Participants will be encouraged to return all unused/
empty study medication packets at weeks 2, 8, and 16 for 
an adherence check (tablet count). Any issues with adher-
ence will be recorded in the eCRF. Participants who are 
nonadherent will be encouraged and can be reminded by 
telephone, text, or email.
Investigator withdrawal
Participants may be withdrawn from the study medica-
tion on safety grounds, at investigator discretion. All study 
drug withdrawals will be recorded in the eCRF. Reasons for 
investigator withdrawal are found in Table  3. Participants 
may remain in the study, at investigator discretion, without 
taking the medication and will not be replaced.
Treatment interruptions
Treatment may be interrupted at investigator discretion. 
Participant will be reviewed by the investigator who will de-
termine if suitable to continue in the study and when/if the 
drug is to be restarted. Interruptions will be logged in the 
eCRF. If an interruption is more than 1 and up to 21 days, the 
study period may be lengthened. An interruption of more 
than 21  days will prompt withdrawal from study. Interim 
study visits may be scheduled as required.
Adverse events
Adverse events must be assessed and recorded in the 
participant’s case notes. Only Related Unexpected Serious 
Adverse Events (RUSAEs) are to be collected in an expedited 
manner and reported to the sponsor. An RUSAE is an unex-
pected event that is thought to be related to a trial-specific 
procedure and/or the study drug, with reference to the most 
recent SmPC.11
RUSAEs will be reported via the eCRF to the 
Pharmacovigilance Office within 24 hours of the site be-
coming aware of the event. The local principal investigator 
(or designee) must ensure that any missing information is 
entered into the eCRF.
Post-trial care
At the final study visit, the participant will be reviewed by 
an investigator who will advise on further antihypertensive 
therapy and communicate with the participant’s general 
practice. There is no provision for the supply of torasemide 
after the trial has ended.
Study procedures
Home BP monitoring. The HBPM device (Omron M3) 
will be posted to the participant during screening and BP will 
be measured using the British & Irish Hypertension Society 
(BIHS) recommended method.12 HBPM will be measured in 
triplicate, morning and evening, over 5 days, during a 10-day 
period.13 The first reading from each set will be omitted and 
the average of the remaining recorded as HBPM. HBPM 
will be entered through the study website or in paper form 
during screening, and by completion of the HBPM diary14 at 
weeks 4 and 12.
Study visit BP monitoring. Study visit BP will be meas-
ured using the method recommended by the BIHS15 with a 
validated, automated Omron BP monitor. After 5 minutes 
rest, 3 BP measurements will be taken, 1 minute apart with 
the average of the second and third recorded as visit BP.
Ambulatory BP monitoring. Ambulatory BP 
monitoring (ABPM; Spacelabs 90217RM) over 24 hours 
will be measured at baseline, weeks 8 and 16 and will 
be used for the assessment of the study outcomes. BIHS 
Standard Operating Procedure, patient information leaflets 
and diaries will be used.16–18 ABPM measured for 24 hours 
with daytime readings every 30 minutes (0800–2159) and 
nighttime readings every 60 minutes (2200–0759). ABPM 
valid if 14 daytime measurements are obtained.15 With the 
exception of the baseline ABPM, participants must have 
been taking the study drug for at least 28  days prior to 
ABPM.
Genotyping. A 2-ml saliva sample will be collected using 
an Isohelix GeneFiXGFX-02 kit as per as the manufacturer’s 
guidelines. DNA quantification will be done using NanoDrop 
Lite Spectrophotometer (Thermo Scientific). Genotyping 
for rs13333226 will be performed using TaqMan SNP 
Genotyping  Assay ID C_31122293_10, context sequence 
[VIC/FAM]: GTCAAAGAGGTAGCACAGCTGTAGG 
[A/G]ATATTGACTCCTCTTCCCAAACAGC. DNA con-
centration of 5 ng/µl will be used with the TaqMan probes 
and TaqMan Universal Master Mix II, no UNG (Applied 
Biosystems) to a total reaction volume of 5 µl. This will be 
amplified and read using QuantStudio 12K Flex (Applied 
Biosystems) and the genotype read using allelic discrimina-
tion plot.
Table 3. Clinical reasons for withdrawal of participants
Illness requiring hospitalization that is likely to preclude further study participation.
Known side-effects of the trial drug which are considered intolerable by the participant.
Extreme electrolyte disturbances or renal dysfunction.
Hypotension—If the patient has symptoms consistent with hypotension and clinic systolic BP is <110 mm Hg or the change in BP from 
previous reading is >30 mm Hg, and in the opinion of the investigator there is no self-limiting reason for hypotension (e.g., episode of 
dehydration, climatic conditions).
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Study samples
Blood samples will be sent to local NHS hospital 
laboratories. Urinary uromodulin assays will be performed, 
at the University of Glasgow laboratory, using a commercially 
available ELISA, as recommended by the manufacturer.
Ethics approval and study registration
Study approved by the West of Scotland Research Ethics 
Committee 5; 16/WS/0160. The trial will be carried out in 
accordance with the Helsinki Declaration of 1975 (as re-
vised in 1983). Registration at clinicaltrials.gov; trial iden-
tifier NCT03354897 and UK Clinical Research Network; 
GN14CE40032060. Current protocol version 2.3 (09/09/2019).
Study objectives and statistical analysis
Primary outcome. The primary outcome is the change 
in 24-hour ABPM SBP AUC (area under the curve) between 
baseline and the end of treatment.
Secondary outcomes. Secondary outcomes are the 
change in:
 • 24-hour ABPM DBP AUC between baseline and the end 
of treatment,
 • daytime ABPM SBP and DBP AUC between baseline and 
the end of treatment,
 • nighttime ABPM SBP and DBP AUC between baseline 
and the end of treatment,
 • HBPM SBP and DBP AUC over the study period,
 • serum electrolytes over the study period.
Sample size calculation. Theoretically, the ideal study 
design would be the compare homozygous subjects (AA vs. 
GG). However, this would require screening and genotyping 
over 4,000 patients with uncontrolled hypertension to get 
adequate numbers with homozygous genotypes (as the fre-
quency of individuals with the rarer GG genotype is (0.03) 
given the G allele frequency of 0.18). As the SNP shows and 
additive effect on BP with a population genotype frequency 
ratio of AA to AG/GG of 2:1, a more efficient study design to 
assess genotype effect on BP would be to compare AA vs. AG/
GG. During the trial, the ratio of AA to AG/GG participants 
will be monitored along with the rate of study completion 
so that sufficient participants in each genotype group will be 
recruited to ensure robust power for the final analysis.
Sample size calculations were based on standard formulae 
for a normally distributed outcome, for detecting a differ-
ence in SBP between groups, assuming a SD of 8 mm Hg, 
a ratio of AA to AG/GG participants of 2:1, and successful 
follow-up of 80% of recruited participants. Under these 
assumptions, recruitment of 240 participants will have 90% 
power to detect a 4 mm Hg SBP difference and 81% power 
to detect a 3.5 mm Hg difference between groups. The use 
of baseline-adjusted regression methods will increase the 
power of the study. The use of 24-hour ABPM AUC as the 
primary outcome should also reduce within-subject varia-
bility, and hence increase power.
Statistical analysis
Prior to database lock, study statisticians will not have 
access to genotypic information; statistical analyses will be 
specified in a detailed Statistical Analysis Plan and all statis-
tical analysis programs will be developed and validated using 
dummy genotype data. Following database lock, the true 
genotypes will be made available for analysis. Per-protocol 
(PP) and intention-to-treat (ITT) analysis will be performed.
The primary analysis will use linear regression to compare 
mean 24-hour ABPM SBP AUC between those possessing the 
AA genotype and those possessing the AG/GG genotypes, 
with adjustment for baseline 24-hour ABPM SBP AUC. The 
adjusted mean difference, with a 95% confidence interval 
and associated P value, will be reported. The primary anal-
ysis will be applied to the subgroup of participants who are 
compliant with study procedures, including taking at least 
80% of the target dose of study treatment for at least 28 days 
after any interruption (PP).
Secondary analyses will extend this regression model to 
ITT and to examine the impact of baseline patient charac-
teristics, and to investigate the possibility of interactions 
with genotype. Other outcome measures will be analyzed 
in a similar manner. For outcomes measured at more than 
1 postbaseline time point, repeated measures regression 
methods will also be used.
Adverse events during the trial will be summarized and 
listed, without formal statistical comparison. No imputation 
of missing data will be performed. The primary analysis will 
be judged at a 5% significance level. Other analyses will not 
be adjusted for multiple comparisons. All statistical anal-
ysis will be performed using SAS for Windows v9.3 or R for 
Windows v3.0 or later versions.
Study sponsorship, monitoring, and audit
The study is sponsored by NHS Greater Glasgow and 
Clyde with the trial co-ordinated from the Glasgow site. 
Study protocol alteration will require an amendment, to be 
reviewed by the sponsor, with approval from research ethics 
committee as appropriate.
To enable regulatory authority audit, all original signed 
consent forms, serious adverse events, source documents, 
and detailed records of treatment disposition in accordance 
with good clinical practice principles and local regulations.
Data collection, management, and retention
The Robertson Centre for Biostatistics (RCB) have devel-
oped the eCRF. Access is restricted via a study-specific web 
portal, with only authorized site-specific personnel granted 
permission to enter participant data. The study team will be 
responsible for all entries into the eCRF and will confirm (elec-
tronically) that the data are accurate and complete. Data will 
be validated at the point of entry into the eCRF. Any additional 
data discrepancies will be flagged to the principal investigator 
with data changes recorded to maintain a complete audit trail.
The RCB computer network is fully validated in ac-
cordance with industry and regulatory standards and 
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are firewall protected and preventative system maintenance 
policies are in place to ensure no loss of service. Web servers 
are secured by digital certificates. Data integrity is assured by 
strictly controlled procedures including secure data transfer 
procedures. Data will be retained for a minimum of 5 years.
Dissemination
Study results will be submitted to an international confer-
ence and published in an international peer review journal 
(open access form). A lay summary will be available.
DISCUSSION
The genomics revolution has resulted in over 1,400 
common SNPs associated with BP along with mutations in 
31 genes associated with rare monogenic forms of hyperten-
sion.3 Globally, about 55% of people with hypertension are 
receiving treatment.19 Tailoring of therapy has not progressed 
beyond considering self-reported African ancestry and 
serum renin levels. Strategies to reposition licensed drugs in 
the hypertension care pathway through genomic markers is 
a precision medicine strategy that can help reduce the public 
health burden. We propose to show that using a SNP from 
genome wide association study can identify patients with 
uncontrolled hypertension who will respond better to long 
acting off-patent loop-diuretics. The clinical application of 
this result will be a genotype-guided algorithm to determine 
use of loop-diuretics, and this will be relevant across the 
whole spectrum of hypertensive patients. As hypertension is 
a multifactorial disease, it is likely that the main application 
of our result will be earlier use of loop-diuretics in those with 
AA genotype. Though loop-diuretics may be less efficacious 
as monotherapy than other antihypertensive drug classes, 
they are commonly used in clinical practice for patients with 
difficult to control hypertension and are advocated in the 
European Society of Hypertension guidelines for resistant 
hypertension and the US guidelines as secondary agents. 
If the underlying pathological mechanism is an interaction 
between uromodulin and NKCC2 leading to increased so-
dium absorption in those individuals with high uromodulin 
excretion, then targeting NKCC2 in these individuals with 
loop-diuretics is a valid strategy. Such treatment is cheap, 
easily accessible, has an existing licence and can be clinically 
implemented rapidly. If this study confirms our hypothesis, 
a targeted strategy will improve BP control and reduce the 
global burden of uncontrolled hypertension.
Furthermore, the study design is novel, with genotype 
blinding, rather than the conventional treatment blinding, 
and utilizes a 2-step consent process for screening and in-
clusion into the main study at 3 study sites. These innovative 
methods place the BHF UMOD study in a unique position 
to inform future genotype-directed and precision medicine 
trials for hypertension and also nonhypertension trials.
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